Biomedical Engineering Reference
In-Depth Information
Table 1
Results of anti-ICAM-1 therapy with enlimomab in acute ischemic stroke
Patients, no
NIH Stroke Scale score
p Value*
Treatment
Dead
Alive
0
1-5
6-10
11-15
16-20
>20
Wilcoxon
Proportional
odds
Day 0
Placebo
0
308
0.0
4.9
28.6
26.6
15.9
24.0
Enlimomab
0
315
0.0
5.4
25.7
28.3
17.8
22.9
0.79
NA
Day 5
Placebo
14
294
8.8
28.2
15.6
15.6
11.6
20.1
Enlimomab
23
292
3.8 24.0 18.8
18.2
13.0
22.3
0.03
0.02
Day 30
Placebo
38
270
17.4 36.7 15.9
11.5
7.8
10.7
Enlimomab
52
263
14.4 33.1 18.3
14.1
10.6
9.5
0.17
0.27
Day 90
Placebo
50 258 22.9 40.3 17.4 7.0 6.2 6.2
Enlimomab
70 245 18.4 38.8 19.6 11.8 5.7 5.7 0.17 0.34
h e table indicates NIH Stroke Scale as percentage of surviving patients. Enlimomab has a negative
ef ect on the NIHSS score at 5 d. *p Values compare enlimomab with placebo in patients surviving to
a given study day; proportional odds likelihood ratio tests adjusted for age and baseline NIH score.
(Adapted from Enlimomab Acute Stroke Trial Investigators, 2001.)
References
Bitsch, A. and W. Klene, L. Murtada, H. Prange, and P. Rieckmann. 1998. A longitudinal
prospective study of soluble adhesion molecules in acute stroke. Stroke 29: 2129-2135.
Castellanos, M. and J. Castillo, M. García, R. Leira, J. Serena, A. Chamorro, and A. Dávalos.
2002. Inl ammation-mediated damage in progressing lacunar infarctions. A potential
therapeutic target. Stroke 33: 982-987.
Chen, P.L. and P.Y. Wang, W.H. Sheu, Y.T. Chen, Y.P. Ho, H.H. Hu, and H.Y. Hsu. 2006.
Changes of brachial l ow-mediated vasodilation in dif erent ischemic stroke subtypes.
Neurology 67: 1056-1058.
DeGraba, T.J. and A.L. Sirén, L. Penix, R.M. McCarron, R. Hargraves, S. Sood, K.D. Pettigrew,
and J.M. Hallenbeck. 1998. Increased endothelial expression of intercellular adhesion
molecule-1 in symptomatic versus asymptomatic human carotid atherosclerotic plaque.
Stroke 29: 1405-1410.
del Zoppo, G.J. and G.W. Schmid-Schönbein, E. Mori, B.R. Copeland, and C.M. Chang.
1991. Polymorphonuclear leukocytes occlude capillaries following middle cerebral
artery occlusion and reperfusion in baboons. Stroke 22: 1276-1283.
Enlimomab Acute Stroke Trial Investigators. 2001. Use of anti-ICAM-1 therapy in ischemic
stroke: Results of the Enlimomab Acute Stroke Trial. Neurology 57: 1428-1434.
Fassbender, K. and T. Bertsch, O. Mielke, F. Mühlhauser, and M. Hennerici. 1999. Adhesion
molecules in cerebrovascular disease. Evidence for an inl ammatory endothelial
activation in cerebral large- and small-vessel disease. Stroke 30: 1647-1650.
